Market Overview
On Friday 23 October, the shares of Elutia Inc. (ticker: ELUT) closed at USD 0.87, reflecting a modest gain of 1.48 % over the preceding 24 hours. The trading session concluded at 04:58 PM Central Europe time, during which approximately USD 67 300 worth of the company’s stock changed hands. With a market capitalisation of USD 36.4 million, Elutia remains a small‑cap player in the biotechnology sector.
The company’s price action sits just below its 200‑day simple moving average of USD 0.97. Over the past year, Elutia’s share price has fluctuated between a low of USD 0.50 on 17 December 2025 and a high of USD 1.38 on 4 March 2026. The current level places the stock near its historical low, suggesting that investors may still view the shares as undervalued relative to their 52‑week range.
Comparative Performance
Elutia’s recent performance can be contextualised by examining the movements of several other technology and specialty‑sector stocks during the same 24‑hour period:
| Ticker | 24‑Hour Move | Current Price | Market Capitalisation | Notable Highlights |
|---|---|---|---|---|
| ATNM (Actinium) | +15.94 % | USD 1.53 | USD 43.4 mn | P/E ratio 3.87 |
| BGSF (Bgsf) | +2.21 % | USD 4.32 | USD 43.6 mn | Upcoming Q3 2026 earnings release, Supplier Company of the Year award |
| VRM.MX (Vroom) | +1.02 % | USD 7.79 | USD 43.5 mn | — |
| SPWH (Sportsman’s Warehouse Holdings) | +1.82 % | USD 1.09 | USD 43.1 mn | — |
| GROV (Grove Collaborative) | +2.51 % | USD 1.06 | USD 43.6 mn | — |
While Actinium experienced a sharp rally, the broader group of peers displayed modest gains, indicating a generally positive but cautious market environment for specialty and technology stocks.
Company Snapshot
Elutia Inc. is a biotechnology firm headquartered in the United States, listed on the Nasdaq exchange. The company’s core competency lies in the development of proprietary drug‑eluting biologic technologies that are intended for use in device implantation and soft tissue reconstruction. Through its platform, Elutia seeks to enhance therapeutic delivery while reducing adverse tissue responses. The company’s product pipeline and research efforts are aimed at addressing unmet needs in both medical device and regenerative medicine markets.
For further information about Elutia’s products, research, and corporate governance, interested parties may visit the company’s website at www.elutia.com .
